Dry powder inhalation, part 2: the present and future

References

• Lynch AJ, Rowley CA. The history of grinding. Society for Mining, Metallurgy and Exploration Inc (SME). Littleton. Colorado; 2005.
   Google Scholar
• Gommeren HJC. Study of a closed-circuit jet mill plant using on-line particle size measurements. Delft The Netherlands: Delft University Press; 1997.
   Google Scholar
• American Pulverizing Corporation. Art of pulverizing US16-8717. 1926.
   Google Scholar
• American Pulverizing Corporation. Method of pulverizing minerals and similar materials US1948609. 1934.
   Google Scholar
• International Pulverizing Corporation. Method and apparatus for providing material in finely divided form. 1936. US2032827.
   Google Scholar
• Bell JH, Hartley PS, Cox JSG. Dry powder aerosols I: a new powder inhalation device. J Pharm Sci. 1971;60(10):1559–1564.
   PubMed Web of Science ®Google Scholar
• Gamble JF, Chin W-S, Gray V. Investigation into the degree of variability in the solid-state properties of common pharmaceutical excipients – anhydrous lactose. AAPS PharmSciTech. 2010;11(4):1552–1557.
   PubMed Web of Science ®Google Scholar
• Steckel H, Eskandar F, Borowski M, et al., Selecting lactose for capsule-based dry powder inhaler. PharmTech.com 2004: Cited Jan 2022. Available from: http://www.pharmtech.com/selecting-lactose-capsule-based-dry-powder-inhaler
   Google Scholar
• Guenette E, Barrett A, Kraus D, et al. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design. J Pharm Sci. 2009;380:80–88.
   Google Scholar
• de Boer AH, Hagedoorn P, Gjaltema D, et al. Air classifier technology (ACT) in dry powder inhalation part 4: performance of air classifier technology in the Novolizer multi-dose dry powder inhaler. Int J Pharm. 2006;310(1–2):81–89.
   PubMed Web of Science ®Google Scholar
• Travers DN, White RC. The mixing of micronized sodium bicarbonate with sucrose crystals. J Pharm Pharac. 1971;23:261S.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharma. Method for producing powdery formulations. 2002.
   Google Scholar
• Coulson JM, Maitra NK. The mixing of solid particles. Ind Chem Manuf. 1950;26:55–60.
   Google Scholar
• Hersey JA. Ordered mixing: a new concept in powder mixing practice. Powd Technol. 1975;11(1):41–44.
   Web of Science ®Google Scholar
• Lacey PMC. The mixing of solid particles. Trans Inst Chem Eng. 1943;21:53–59.
   Google Scholar
• Thiel WJ, Lai F, Hersey JA. Comments on ‘suggestions on the nomenclature of powder mixtures. Powd Technol. 1981;28(1):117–118.
   Web of Science ®Google Scholar
• Staniforth JN. Order out of chaos. J Pharm Pharmacol. 1987;39(5):329–334.
   PubMed Web of Science ®Google Scholar
• Staniforth JN. Total mixing.Int J Pharm Technol Prod Manuf. 1981;2:7–12
   Google Scholar
• Grasmeijer F, Grasmeijer N, Hagedoorn P. Recent advances in the fundamental understanding of adhesive mixtures for inhalation. Curr Pharm Design. 2015;21(40):5900–5914.
   PubMed Web of Science ®Google Scholar
• Freundlich MM. Origin of the electron microscope. Sci. 1963;142:185–188.
   PubMed Web of Science ®Google Scholar
• Bogner A, Jouneau P-H, Thollet G, et al. A history of scanning electron microscopy developments: towards ‘wet-STEM’ imaging. Micron. 2007;38(4):390–401.
   PubMed Web of Science ®Google Scholar
• Fussel AL, Grasmeijer F, Frijlink HF, et al. CARS microscopy as a tool for studying the distribution of micronised drugs in adhesive mixtures for inhalation. J Raman Spectroscop. 2014;45(7):495–500.
   Web of Science ®Google Scholar
• Stegemann S. Hard gelatin capsules today – and tomorrow. 2002. cited Jan 2002. Available from: https://cpsl-web.s3.amazonaws.com/kc/library/hard-gelatin-capsules-today-and-tomorrow.pdf
   Google Scholar
• Murdoch J. Capsules for protecting medicinal and other preparations. London, patent 11,937. 1847
   Google Scholar
• Jones BE. A history of DPI capsule filling. Inhalation. 2009;3:20–23.
   Google Scholar
• Jones BE. Pulmonary delivery & dry powder inhalers: advances in hard-capsule technology. ONdrugdelivery 2010; 16-18, cited Mar 2022. Available from: https://www.ondrugdelivery.com/wp-content/uploads/2018/11/Nov2010.pdf
   Google Scholar
• Al-Tabakha MM. HPMC capsules: current status and future prospects. J Pharm Pharmaceut Sci. 2010;13:128–142.
   PubMed Web of Science ®Google Scholar
• Pinto JT, Wutscher T, Stankovic-Brandl M, et al. Evaluation of the physico-mechanical properties and electrostatic charging behavior of different capsule types for inhalation under distinct environmental conditions. AAPS PharmSciTech. 2020;21(128):1–10.
   Google Scholar
• Jolliffe IG, Newton JM, Cooper D. The design and use of an instrumented mG2 capsule filling machine simulator. J Pharm Pharmacol. 1982;34(4):230–235.
   PubMed Web of Science ®Google Scholar
• Jolliffe IG, Newton JM. Practical implications of theoretical consideration of capsule filling by the dosator nozzle system. J Pharm Pharmacol. 1982;34(5):293–298.
   PubMed Web of Science ®Google Scholar
• Janson C, Henderson R, Löfdahl M, et al. Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax. 2020;75(1):82–84.
   PubMed Web of Science ®Google Scholar
• Ramadan WH, Sarkis AT. Patterns of use of dry powder inhalers versus pressurized metered-dose inhalers devices in adult patients with chronic obstructive pulmonary disease or asthma: an observational comparative study. Chronic Respir Dis. 2017;14(3):309–320
   PubMed Web of Science ®Google Scholar
• Duddu SP, Sisk SA, Walter YH, et al. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSpher powder. Pharm Res. 2002;19(5):689–695.
   PubMed Web of Science ®Google Scholar
• Coates MS, Chan H-K, Fletcher DF, et al. Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res. 2005;22(9):1445–1453.
   PubMed Web of Science ®Google Scholar
• Coates MS, Chan H-K, Fletcher DF, et al. Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler. Pharm Res. 2007;24(8):1450–1456.
   PubMed Web of Science ®Google Scholar
• Schur J, Lee S, Adams W, et al. Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers. AAPS J. 1012;14(4):667–676.
   Google Scholar
• Lavorini F, Pistolesi M, Usmani OS. Recent advances in capsule-based dry powder inhaler technology. Multidiscip Resp Med. 2017;12(11):2–7.
   PubMedGoogle Scholar
• Buttini F, Quarta E, Allegrini C, et al. Understanding the importance of capsules in dry powder inhalers. Pharmaceutics. 2021;13(11):1936.
   PubMed Web of Science ®Google Scholar
• de Boer AH, Hagedoorn P, Hoppentocht M, et al. Dry powder inhalation: past, present and future. Expert Opin Drug Deliv. 2016;14(4):499–512.
   PubMed Web of Science ®Google Scholar
• Wetterlin K. Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm Res. 1988;5(8):506–508.
   PubMed Web of Science ®Google Scholar
• Chrystyn H. The DiskusTM: a review of its position among dry powder inhaler devices. Int J Clin Pract. 2007;61(6):1022–1036.
   PubMed Web of Science ®Google Scholar
• Grant AC, Walker R, Hamilton M, et al. The ®ELLIPTA Dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers. J Aerosol Med Pulm Drug Deliv. 2015;28(6):474–485.
   PubMed Web of Science ®Google Scholar
• de Boer AH, Thalberg K. Dry powder inhalers (DPIs). In: Kassinos S, Bäckman P, Conway J, et al., editors. Inhaled medicines. London: Elsevier Academic Press; 2021:99–146.
   Google Scholar
• Vaidya S, Ziegler D, Tanase A-M, et al. Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers. Pulm Pharmacol Ther. 2021;70:102019.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Cavalli F, Usmani OS, et al. Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Exp Opin Drug Deliv. 2020;17(5):635–646.
   PubMed Web of Science ®Google Scholar
• Steuer G, Prais D, Mussaffi H, et al. Inspiromatic-safety and efficacy study of a new generation dry powder inhaler in asthmatic children. Pediatr Pulmonol. 2018;53(10):1348–1355.
   PubMed Web of Science ®Google Scholar
• Hirst PH, Newman SP, Clark DA, et al. Lung deposition of budesonide from the novel dry powder inhaler AirmaxTM. Resp Med. 2002;96(6):389–396.
   PubMed Web of Science ®Google Scholar
• Dolovich M, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011;377(9770):1032–1045.
   PubMed Web of Science ®Google Scholar
• DeHaan WH, Finlay WH. Predicting extrathoracic deposition from dry powder inhalers. Aerosol Sci. 2004;35(3):309–331.
   Web of Science ®Google Scholar
• Usmani OS, Biddisombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. Am J Respir Crit Care Med. 2005;172(12):1497–1504.
   PubMed Web of Science ®Google Scholar
• Heinemann L. The failure of Exubera: are we beating a dead horse? J Diabetes Sci Technol. 2008;2(3):518–529.
   PubMedGoogle Scholar
• Xiroudaki A, Schoubben A, Giovagnoli S, et al. Dry powder inhalers in the digitalization era: current status and future perspectives. Pharmaceutics. 2021;13(9):1455.
   PubMed Web of Science ®Google Scholar
• Eskandar F, Lejeune M, Edge S. Low powder mass filling of dry powder inhalation formulations. Drug Developm Ind Pharm. 2011;37(1):24–32
   PubMed Web of Science ®Google Scholar
• Sitz R. Current innovations in dry powder inhalers. ONdrugdelivery, 2010, https://www.ondrugdelivery.com/wp-content/uploads/2018/11/Nov2010.pdf Cited Apr 2022
   Google Scholar
• Angelo R, Rousseau Grant M, et al. Technosphere insulin: defining the role of Technosphere particles at the cellular level. J Diabetes Sci Technol. 2009;3(3):545–554.
   PubMedGoogle Scholar
• Valdes J, Shipley T, Rey JA. Loxapine inhalation powder (Adasuve). A new and innovative formulation of an antipsychotic treatment for agitation. P&t. 2014;39:621–623.
   PubMedGoogle Scholar
• de Boer AH, Gjaltema D, Hagedoorn P, et al. Comparative in vitro performance evaluation of the Novopulmon 200 Novolizer and Budesonid-Ratiopharm Jethaler: two novel budesonide dty powder inhalers. Pharmazie. 2004;59(9):692–699.
   PubMed Web of Science ®Google Scholar
• Newman S, Malik S, Hirst P, et al. Lung deposition of salbutamol in healthy human subjects from the MAGhaler dry powder inhaler. Resp Med. 2002;96(12):1026–1032.
   PubMed Web of Science ®Google Scholar
• Krishna BS, Nikhilesh GSS, Tarun B, et al. Industrial production of lactic acid and its applications. Int J Biotech Res. 2018;1. 43–54.
   Google Scholar
• Komesu A, Rocha de Oliveira JA, da Silva Martins LH, et al. Lactic acid production to purification: a review. BioResources. 2017;12(2):4364–4383.
   Web of Science ®Google Scholar
• van den Oever M, Molenveld K, van der Zee M, et al. Bio-based and biodegradable plastics- facts and figures. Wageningen, Food & Biobased Research, report 1722
   Google Scholar
• Farooqi S, Ram S, Shehzadi A, et al. Lactic acid production using various raw materials and microorganisms. Annals Life Sci. 2019;5. 1–8.
   Google Scholar
• Wellenreuther C, Wolf A, Zander N. Cost competitiveness of sustainable bioplastic feedstocks – a Monte Carlo analysis for polylactic acid. 2022;Cleaner Eng Technol. 6:100411.
   Google Scholar
• Post PM, Hogerwerf L, Bokkers EAM, et al. Effects of Dutch livestock production on human health and the environment. Sci Total Environ. 2020; 737: 139702.
   PubMed Web of Science ®Google Scholar
• Tonnis WT, Lexmond AJ, Frijlink HW, et al. Devices and formulations for pulmonary vaccination. Expert Opin Drug Deliv. 2013;10(10):1383–1397.
   PubMed Web of Science ®Google Scholar
• de Boer AH, Hagedoorn P. The role of disposable inhalers in pulmonary drug delivery. Exp Opin Drug Deliv. 2015;12(1):143–157.
   PubMed Web of Science ®Google Scholar
• van der Palen J, van der Valk P, Goosens M, et al. A randomised cross-over trial investigating the ease of use and preference of two dry powder inhalers in patients with asthma and chronic obstructive pulmonary disease. Exp Opin Drug Deliv. 2013;10(9):1171–1178.
   PubMed Web of Science ®Google Scholar
• Zervas E, Samitas K, Gaga M. Assessment of satisfaction with different dry powder inhalation devices in Greek patients with COPD and asthma: the ANASA study. Int J COPD. 2016;11:1845–1855.
   Google Scholar
• Schreiber J, Sonnenburg T, Luecke E. Inhaler devices in asthma and COPD patients – a prospective cross-sectional study on inhaler preferences and error rates. BMC Pulm Med. 2020;20(1):222.
   PubMed Web of Science ®Google Scholar
• Dellamary LA, Tarara TE, Smith DJ, et al. Hollow porous particles in metered dose inhalers. Pharm Res. 2000;17(2):168–174.
   PubMed Web of Science ®Google Scholar
• Schur J, Price R, Lewis D, et al. From single excipients to dual excipient platforms in dry powder inhaler products. Int J Pharm. 2016;514(2):374–383.
   PubMedGoogle Scholar
• Buttini F, Brambilla G, Copelli D, et al. Effect of flow rate on in vitroaerodynamic performance of ®NEXThaler in comparison with ®Diskus and turbohaler® dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2016;29(2):167–178.
   PubMed Web of Science ®Google Scholar
• Sørli JB, Sivans KB, Da Silva E, et al. Bile salt enhancers for inhalation: correlation between in vitro and in vivo lung effects. Int J Pharm. 2018;550(1–2):114–122.
   PubMedGoogle Scholar
• Shetty N, Cipolla D, Park H, et al. Physical stability of dry powder inhaler formulations. Expert Opin Drug Deliv. 2020;17(1):77–96.
   PubMed Web of Science ®Google Scholar
• Edwards DA, Hanes J, Caponetti G. Large porous particles for pulmonary drug delivery. Science. 1997;276(5320):1868–1872.
   PubMed Web of Science ®Google Scholar
• Coates MS, Fletcher DF, Chan H-K, et al. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics Part 1: grid structure and mouthpiece length. J Pharm Sci. 2004;93(11):2863–2876.
   PubMed Web of Science ®Google Scholar
• de Boer AH, Hagedoorn P, Woolhouse R, et al. Computational fluid dynamics (CFD) assisted performance evaluation of the TwincerTM disposable high-dose dry powder inhaler. J Pharm Pharmacol. 2012;64(9):1316–1325.
   PubMed Web of Science ®Google Scholar
• Walenga RL, Worth Longest P. Current inhalers deliver very small doses to the lower tracheobronchial airways: assessment of healthy and constricted lungs. J Pharm Sci. 2016;105(1):147–159.
   PubMed Web of Science ®Google Scholar
• Koullapis P, Olsson B, Kassinos SC, et al. Multiscale in silico lung modelling strategies for aerosol inhalation therapy and drug delivery. Curr Opin Biomed Eng. 2019;11:130–136.
   PubMedGoogle Scholar
• Worth Longest P, Bass K, Dutta R, et al. Use of computational fluid dynamics deposition modelling in respiratory drug delivery. Expert Opin Drug Deliv. 2019;16(1):7–26.
   PubMed Web of Science ®Google Scholar
• Kassinos S, Bäckman P, Conway J, et al., eds. Inhaled medicines. Optimizing development through integration of in silico, in vitro and in vivo approaches. London: Elzevier Academic Press; 2021.
   Google Scholar
• van Holsbeke C, De Backer J, Vos W, et al. Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size in lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler. Ther Adv Respir Dis. 2018;12:1–15.
   Web of Science ®Google Scholar
• Newhouse MT, Hirst PH, Dudda SP. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest. 2003;124(1):360–366.
   PubMed Web of Science ®Google Scholar
• Geller DE, Weers J, Heuerding S. Development of an inhaler dry-powder formulation of tobramycin using pulmospheretm technology. J Aerosol Med Pulm Drug Deliv. 2011;24(4):175–182.
   PubMed Web of Science ®Google Scholar
• Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25(5):999–1022.
   PubMed Web of Science ®Google Scholar
• Staniforth JN. Carrier particles for use in dry powder inhalers. 2010;8(920):781.
   Google Scholar
• Begat P, Price R, Harris H, et al. The influence of force control agents on the cohesive-adhesive balance in dry powder inhaler formulations. Kona. 2005;23(1):109–121.
   Google Scholar
• Tian G, Worth Longest P, Li X, et al. Targeting aerosol deposition to and within the lung airways using excipient enhanced growth. J Aerosol Med Pulm Drug Deliv. 2013;26(5):248–265.
   PubMed Web of Science ®Google Scholar
• Corradi M, Chrystyn H, Corsio BG, et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclomethasone and formoterol to treat large and small airways in asthma. Exp Opin Drug Deliv. 2014;11(9):1497–1506.
   PubMed Web of Science ®Google Scholar
• Dinh K, Myers DJ, Glazer M, et al. In vitro aerosol characterization of Staccato loxapine. Int J Pharm. 2011;403(1–2):101–108.
   PubMedGoogle Scholar
• Spyker DA, Cassella JV, Stoltz RR, et al. Inhaled loxapine and intramuscular lorazepam in healthy volunteers: a randomized placebo-controlled drug-drug interaction study. Pharm Res Per. 2015;3:e00194.
   PubMed Web of Science ®Google Scholar
• Pritchard JN. The climate is changing for metered-dose inhalers and action is needed.Drug Design Dev Ther 2020; 14:3043–3055.
   PubMed Web of Science ®Google Scholar
• Chrystyn H, van der Palen J, Sharma R, et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. Prim Care Respir Med. 2017;27(1):22.
   PubMedGoogle Scholar
• Castel-Branco MM, Fontes A, Figueiredo IV. Identification of inhaler technique errors with a routine procedure in Portuguese community pharmacy. Pract Pharm. 2017;15:1072.
   PubMed Web of Science ®Google Scholar
• Pessôa CL, Mattos MJ, Alho AR, et al. Most frequent errors in inhalation technique of patients with asthma treated at a tertiary care hospital. Einstein (São Paulo). 2019;17(2):eAO4397.
   PubMed Web of Science ®Google Scholar
• Ngo CQ, Phan DM, Vu GV, et al. Inhaler technique and adherence to inhaled medications among patients with acute exacerbation of chronic obstructive pulmonary disease in Vietnam. Int J Environ Res Public Health. 2019;16(2):185.
   Web of Science ®Google Scholar
• Verrips A, Hoogendoorn S, Jansema-Hoekstra, et al. The circular economy of plastics in the Netherlands. In: So W, Chow C, Lee J, editors. Environmental Sustainability and education for waste management. Singapore: Springer; 2019 https://org/10.1007/978-981-13-9173-6_4.
   Google Scholar
• Zheng J, Suh S. Strategies to reduce the global carbon footprint of plastics. Nat Climate Change. 2019;9(5):374–378.
   Web of Science ®Google Scholar
• Wilkinson AJ, Braggins R, Steinbach I, et al. Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England. BMJ Open. 2019;9(10):e028763.
   PubMed Web of Science ®Google Scholar
• United States Environmental Protection Agency (EPA) report ‘overview of greenhouse gases. 2022, Cited Apr 2022. Avilable from: https://www.epa.gov/ghgemissions/overview-greenhouse-gases
   Google Scholar
• Jason C, Henderson R, Löfdahl M, et al. Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax. 2020;75(1):82–84.
   PubMed Web of Science ®Google Scholar
• Solvay (Daikin) Solkane HFA-227 and HFA-134A datasheet cited Apr 2022. Avilable from: https://www.daikinchem.de/sites/default/files/pdf/Propellants/Daikin%20Propellants%20-%20Solkane%20227,%20134a%20pharma.pdf
   Google Scholar
• Carton W, Lund JF, Dooley K. Undoing equivalence: rethinking carbon accounting for just carbon removal. Front Clim. 2021. DOI:10.3389/fclim.2021.664130.
   PubMedGoogle Scholar
• Voulvoulis N, Kirkman R, Giakoumis T, et al. Examining material evidence, the carbon fingerprint, 2019, cited Apr 2022. Avilable from: www.imperial.ac.uk/media/imperial-college/faculty-of-natural-sciences/centre-for-environmental-policy/public/Veolia-Plastic-Whitepaper.pdf
   Google Scholar
• Shen M, Huang W, Chen M, et al. (Micro)plastic crisis: un-ignorable contribution to global greenhouse gas emissions and climate change. J Cleaner Prod. 2020;254:120138.
   Web of Science ®Google Scholar
• Irfan M, Ahmad M, Fareed Z, et al. On the indirect environmental outcomes of COVID-19: short0term revival with futuristic long-term implications, 2021
   Google Scholar
• Mäkelä MJ, Backer V, Hedegaard M, et al. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107(10):1481–1490.
   PubMed Web of Science ®Google Scholar
• Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol. 2004;114(6):1288–1293.
   PubMed Web of Science ®Google Scholar
• Parisini I, Cheng SJ, Symons DD, et al. Potential of a cyclone prototype spacer to improve in vitro dry powder delivery. Pharm Res. 2014;31(5):1133–1145.
   PubMed Web of Science ®Google Scholar
• Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018; 19(1). 10.1186/s12931-017-0710-y
   Google Scholar
• Capanoglu M, Misirlioglu ED, Toyran M, et al. Evaluation of inhaler technique, adherence to the therapy and their effect on disease control among children with asthma using metered dose or dry powder inhalers. J Asthma. 2015;52(8):838–845.
   PubMed Web of Science ®Google Scholar
• Sriram KB, Percival M. Suboptimal inhaler medication adherence and incorrect technique are common among chronic obstructive pulmonary disease patients. Chronic Respir Dis. 2016;13(1):13–22
   PubMed Web of Science ®Google Scholar
• Suppli Ulrik C, Backer V, Søes-Petersen, et al. The patient’s perspective: adherence or non-adherence to asthma controller therapy? J Asthma. 2006;43(9):701–704.
   PubMed Web of Science ®Google Scholar
• Bosley CM, Fosbury JA, Cochrane GM. The psychological factors associated with poor compliance with treatment in asthma. Eur Respir J. 1995;8(6):899–904.
   PubMed Web of Science ®Google Scholar
• Lycett H, Wildman E, Raebel EM, et al. Treatment perceptions in patients with asthma: synthesis of factors influencing adherence. Respir Med. 2018; 141: 180–189.
   PubMed Web of Science ®Google Scholar
• Haughney J, Barnes G, Partridge M, et al. The living & breathing study: a study of patients’ views of asthma and its treatment. Primary Care Respir J. 2004;13(1):28–35.
   PubMedGoogle Scholar
• Lexmond AJ, Hagedoorn P, Frijlink HW, et al. Prerequisites for a dry powder inhaler for children with cystic fibrosis. Plos One. 2017;12(8):e0183130.
   PubMed Web of Science ®Google Scholar
• Luinstra M, Isufi V, de Jong L, et al. Learning from Parkinson’s patients: usability of the Cyclops dry powder inhaler. Int J Pharm. 2019;567:118493.
   PubMedGoogle Scholar
• Weers J. Inhaled antimicrobial therapy – Barriers to effective treatment.Advanced Drug Deliv Rev. 2015; 85:24–43.
   PubMed Web of Science ®Google Scholar
• Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the Eager trial. J Cyst Fibros. 2011;10(1):54–61.
   PubMed Web of Science ®Google Scholar
• Hamed K, Conti V, Tian H, et al. Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis if US insurance claims data. Patient Preference Adherence. 2017;11:831–838.
   PubMed Web of Science ®Google Scholar
• Latchford G, Duff A, Quinn J, et al. Adherence to nebulised antibiotics in cystic fibrosis. Patient Edu Couns. 2009;75(1):141–144.
   PubMed Web of Science ®Google Scholar
• Howell IB, Tugwell A, Bhaskaran D, et al. Adherence to nebulised therapies in people with cystic fibrosis starting Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio). Thorax. 2021;76(Suppl 2):A40.
   Google Scholar
• CHMP’s assessment report for paediatric studies submitted according to Article 46 of the Regulation (EC) No 1901/2006 TOBI Podhaler. 533035. EMA. 2016.
   Google Scholar
• Anderson P. Patient preference for and satisfaction with inhaler devices. Eur Respir Rev. 2005;14(96):109–116.
   Google Scholar